Attached files
| file | filename |
|---|---|
| EX-99.01 - EXHIBIT 99.01 - Inspyr Therapeutics, Inc. | v357985_ex99-01.htm |
| EX-99.02 - EXHIBIT 99.02 - Inspyr Therapeutics, Inc. | v357985_ex99-02.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 23, 2013 (October 21, 2013)
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
| Delaware | 0001421204 | 20-0438951 | ||
|
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01 | Other Events. |
On October 22, 2013, GenSpera, Inc. announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma (liver cancer), presented final data from the G-202 Phase I clinical on October 21, 2013 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA (http://www.aacr.org/home/scientists/meetings—workshops/molecular-targets-and-cancer-therapeutics.aspx). A copy of the press release and poster used in the presentation are attached hereto as Exhibits 99.01 and 99.02, respectively.
| Item 9.01 | Financial Statements and Exhibits. |
|
Exhibit No. |
Description | |
| 99.01 | Press Release issued October 22, 2013 | |
| 99.02 | Poster used in connection with October 21, 2013 presentation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 23, 2013
| GenSpera, Inc. | ||
| By: | /s/ Craig Dionne | |
| Craig Dionne | ||
| Chief Executive Officer | ||
INDEX OF EXHIBITS
|
Exhibit No. |
Description | |
| 99.01 | Press Release issued October 22, 2013 | |
| 99.02 | Poster used in connection with October 21, 2013 presentation |